Alira Health

Alira Health

The Evolution of Patient Engagement

Published on:
February 10, 2022
Annabel de Maria

Annabel de Maria

Chief Patient Officer at Alira Health

Interview with Annabel de Maria, Chief Patient Officer of Alira Health

Patient engagement is becoming more critical than ever in successfully delivering a drug or device to market. To learn how patient engagement is evolving and what is next for it, we talked to Annabel de Maria, industry expert in the field with over 25 year of experience and Chief Patient Officer of Alira Health.

How did you come to work in patient engagement?

Annabel: My journey in patient engagement started 22 years ago when we launched the first Erectile Dysfunction treatment in Spain—and the launch completely failed. Patients didn’t show up to their doctor appointments, and we had to go back and ask them why. Patients explained they didn’t want to have the Erective Dysfunction conversation with their doctor. Knowing this allowed us to understand how we could better support patients in the process.

That launch changed the way I viewed marketing and communications in biopharma—I understood that unless I was able to create a full picture of the patient journey, regardless of disease, bringing a new drug to market could fail. And, most importantly, it is the patients who can best explain their needs, so it’s critical to engage them at the very beginning of the lifecycle management. So, I’ve dedicated my life to engaging patients in the development process, making sure all the products I contribute to become truly valuable for patients and successful for the companies bringing them to the market.

You are heading a dedicated Patient Engagement practice in Alira Health – why did the company decide to take a decision to create this dedicated team? 

Annabel: At Alira Health, we truly believe that patients are at the center of everything we do. We created this practice to provide that patient-centric layer to our existing practices, like clinical research, global market access, regulatory, and Real-World Evidence.

We help our clients bring the vision and the experience of the patient into each stage of the lifecycle management of a drug or medtech device so they can secure better outcomes for patients.

When did patient engagement really come into focus?

Annabel: When I look back 25 years ago, biopharma’s relationship with patient associations was mostly for disease awareness campaigns. They did not focus on the importance of the vision of the patient and did not strive to include the voice of the patient in the product development lifecycle.

Regulatory bodies were the first to engage patients directly. Over the last 10 years, there’s been significant improvement in regulators including patient voices on their boards. Today we see at the EMA and FDA level that patients are very present during the assessment of new drugs, as well as during the approval of drugs. Regulatory bodies consult patients, they’re part of the assessment, and they have a voice and an opinion that is being heard.

Where is there still room for more patient inclusion?

Annabel: When it comes to price and reimbursement process at local level, the HTA agencies, we still have far to go. Some of them, like the NICE in the UK, SMC in Scotland, and CADTH in Canada, are more advanced than others. And in the Catalonia region of Spain, patients are very present on the boards of assessing new drugs and even have a vote. For some specific cases in Canada in pCODR, patients also have a vote, notably with cancer treatments. More and more we see the GBA in Germany, the HAS in France and the AEMPS in Spain engaging with patients and consulting them at the time of the assessment. You can learn more about patient engagement in HTAs in our recent report.

And how are companies evolving their patient engagement strategies?

Annabel: When it comes to biopharma companies, specifically, patients have more and more voice. In recent years, these companies have become much more conscious of the role of patients in product development, including them from the clinical research stage getting input on clinical trials—how companies could improve the design, how to avoid dropout rates, and resubmissions of the protocols. Patients are also very present to help companies understand the full patient journey, particularly so they can be aware of the barriers and gaps that patients face.

When a company wants to define its business plans for the global market, it needs more focus on the real needs of the patient and find a way to support them along the full journey.  Biopharmaceuticals are very conscious of this and are involving patients to design patient support programs that will help them in their everyday, real lives. We still have more improvements to make, but we see a lot of companies recognizing and acting on the importance of being patient centered.

How has this evolution changed the relationship between patients and companies?

Annabel: The relationship between patients and companies has really been impacted by patient associations. You can find examples like EURORDIS and the European Patients’ Forum (EPF) in Europe, and the National Health Council (NHC) in the U.S. These powerful advocacy groups are seen by companies as very strong, empowered partners and industry really acknowledges them. A good example is the conferences organized by EURORDIS, EPF, and NHC—these conferences deliver such a high level of content, you can see they’re being taken very seriously by all the stakeholders in healthcare.

How can your organization keep patients engaged at each stage of the lifecycle? We help organizations engage with patients in a compliant manner to maximize product potential, outcomes, and experience. For more information, contact Annabel de Maria, or connect with her on LinkedIn.

Related news

Articles May 3, 2024
Successful Patient Advisory Boards: What Sponsors Need to Know
Discover five essential keys to a successful Patient Advisory Board (PAB) that can provide actionable feedback to guide you on all stages of development.
Patient Centricity Patient Engagement
Events April 24, 2024
MGFA National Patient Conference 2024
We are pleased to share that we will be participating in MGFA National Patient Conference 2024 as speakers and exhibitors.
Digital Health Innovation Myasthenia Gravis (MG) Patient Engagement Rare Disease
Events April 10, 2024
European Patients as Partners in Clinical Research 2024
Join our panel at the European Patients as Partners event: "The Impact of Patient Involvement Along the Product Lifecycle."
Patient Centricity Patient Engagement
Case Studies March 26, 2024
Pharma Company Overcomes Launch Challenges with Patient-Centric Strategy
Our patient engagement team helped this pharma client identify the drivers behind the challenges they faced with their product launch.
Patient Centricity Patient Engagement Pharma
Articles March 13, 2024
Strategic Patient Engagement as a Game Changer for Your Product Success
This FAQ addresses popular questions about how to make patient engagement the core of a product development and commercialization strategy.
Patient Centricity Patient Engagement
Case Studies March 12, 2024
Pharma Company Adopts a Patient-Centric Value Proposition for Regulatory and Payer Dossier
A pharma company had a wealth of patient data on a product in development and they wanted to create a long-term strategy that would create a continuity of patient engagement across(...)
Patient Centricity Patient Engagement Pharma
Articles February 21, 2024
The Importance of Involving Patients in the Health Technology Assessment Process for Rare Diseases
Experts Annabel de Maria and Ahmad Bechara share how engaging rare disease patients in the HTA process gives them the opportunity to have a meaningful impact.
Healthcare Technology Patient Engagement Rare Disease
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.